Literature DB >> 6682011

Bowman-Birk soybean protease inhibitor as an anticarcinogen.

J Yavelow, T H Finlay, A R Kennedy, W Troll.   

Abstract

Vegetarian populations show a decreased occurrence of breast, colon, and prostatic cancers. Epidemiological studies have identified seeds (maize, corn, and beans) as protective agents in these cancers. We have selected to study one abundant component of all seeds, protease inhibitors. Synthetic and natural protease inhibitors have been shown to inhibit tumor promotion in vivo and in vitro. In the present study, we report that a typical, natural protease inhibitor, the Bowman-Birk inhibitor isolated from soybeans, survives inactivation by stomach digestion in rodents and appears to be fully active as a protease inhibitor in the small intestine, where it complexes with the proteases occurring there, i.e., trypsin and chymotrypsin. A large part of the inhibitor is excreted as protease:protease inhibitor complexed in the feces. We also report the specific inhibition of transformation caused by ionizing radiation by this protease inhibitor. The mechanism of anticarcinogenesis of ingested protease inhibitors may involve the indirect effect of partially blocking protein absorption. High-protein and high-fat diets are known to increase cancer occurrence. Protease inhibitors reaching specific sites also have anticarcinogenic activities, as demonstrated by the radioprotective effect of a protease inhibitor in vitro. The relative importance of the indirect and direct action of protease inhibitors remains to be established.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6682011

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis.

Authors:  Gary R Lichtenstein; Julius J Deren; Seymour Katz; James D Lewis; Ann R Kennedy; Jeffrey H Ware
Journal:  Dig Dis Sci       Date:  2007-06-06       Impact factor: 3.199

2.  Isolation, characterization, and properties of a trypsin-chymotrypsin inhibitor from amaranth seeds.

Authors:  S Tamir; J Bell; T H Finlay; E Sakal; P Smirnoff; S Gaur; Y Birk
Journal:  J Protein Chem       Date:  1996-02

3.  Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-ray-induced transformation in vitro.

Authors:  J Yavelow; M Collins; Y Birk; W Troll; A R Kennedy
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

4.  Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis.

Authors:  J H Ware; X S Wan; P Newberne; A R Kennedy
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

5.  Pyrene acts as a cocarcinogen with the carcinogens benzo[a]pyrene, beta-propiolactone and radiation in the induction of malignant transformation in cultured mouse fibroblasts; soybean extract containing the Bowman-Birk inhibitor acts as an anticarcinogen.

Authors:  N Baturay; A R Kennedy
Journal:  Cell Biol Toxicol       Date:  1986-03       Impact factor: 6.691

6.  Inhibition of 'in vitro' tumor cell growth by aromatic polyamidines exhibiting antiproteinase activity.

Authors:  C Nastruzzi; G Feriotto; D Spandidos; R Ferroni; M Guarneri; R Barbieri; R Gambari
Journal:  Clin Exp Metastasis       Date:  1989 Jan-Feb       Impact factor: 5.150

7.  Initiation of a transplantable fibrosarcoma by the synergism of two non-initiators, alpha-tocopherol and soya oil.

Authors:  P Constantinides; M Harkey
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

8.  Anti-tumoral effects of a trypsin inhibitor derived from buckwheat in vitro and in vivo.

Authors:  Chong-Zhi Bai; Ma-Li Feng; Xu-Liang Hao; Zhi-Juan Zhao; Yu-Ying Li; Zhuan-Hua Wang
Journal:  Mol Med Rep       Date:  2015-04-20       Impact factor: 2.952

9.  Effects of Tepary bean (Phaseolus acutifolius) protease inhibitor and semipure lectin fractions on cancer cells.

Authors:  Teresa García-Gasca; Marlen García-Cruz; Elisa Hernandez-Rivera; Josue López-Matínez; Ana L Castañeda-Cuevas; Lorena Yllescas-Gasca; Adriana J Rodríguez-Méndez; Elizabeth Mendiola-Olaya; José L Castro-Guillén; Alejandro Blanco-Labra
Journal:  Nutr Cancer       Date:  2012       Impact factor: 2.900

10.  Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate.

Authors:  Lilie L Lin; Rosemarie Mick; Jeffrey Ware; James Metz; Robert Lustig; Neha Vapiwala; Ramesh Rengan; Ann R Kennedy
Journal:  Oncol Lett       Date:  2014-02-05       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.